Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy ...

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

CEO Christophe Weber commented. Rusfertide, a treatment for chronic blood disorder polycythemia vera that Takeda bought from Protagonist Therapeutics for $300 million last year, already delivered ...

Takeda chief executive officer, Christophe Weber, commented: “Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our ...

Takeda chief executive officer, Christophe Weber, commented: “Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Asia-Pacific markets were set to mostly climb Friday, tracking Wall Street gains after U.S. President Donald Trump announced ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & ...